a Department of Infectious Diseases , The Second Hospital of Nanjing, The Second Affiliated Hospital of Southeast University , Nanjing , Jiangsu , China.
b Departments of Laboratory Medicine and Infectious Diseases , Nanjing Drum Tower Hospital and Jiangsu Key Laboratory for Molecular Medicine, Nanjing University Medical School , Nanjing , Jiangsu , China.
Hum Vaccin Immunother. 2018 Feb 1;14(2):456-463. doi: 10.1080/21645515.2017.1397243. Epub 2017 Dec 6.
The significance of vaccination against hepatitis B during infancy is recognized worldwide, however, whether booster or revaccination after a period of time following the primary vaccination is required remains controversial. Recently, cross-sectional epidemiological surveys found that HBsAg prevalence in subjects born after the implementation of mass vaccination was increased with age, which was attributed to waning of anti-HBs over time. However, comprehensive analysis of the closely related cross-sectional surveys showed that the age-specific increased HBsAg prevalence was more likely associated with the carry-over of the infection occurred in early life, likely due to imperfect coverage of hepatitis B vaccination at the beginning of its introduction. Latest studies showed that booster response could be observed in the majority of individuals vaccinated 30 years ago. Moreover, confirmed breakthrough HBV infection with severe consequences in successfully vaccinated individuals is extremely rare. Thus far no compelling evidence has been acquired to support booster vaccination in adolescence. The uncertainty regarding the duration of protection of hepatitis B vaccination, especially beyond 30 years after the primary vaccination, merits a systematically designed study to follow the same cohort of participants longitudinally, which differs from the cross-sectional studies reported previously, can hopefully offer more direct evidence to help us to determine whether revaccination of hepatitis B vaccine is necessary.
乙型肝炎疫苗接种在婴儿期的重要性已得到全球认可,但在初次接种后是否需要进行加强或复种仍存在争议。最近的横断面流行病学调查发现,在大规模疫苗接种实施后出生的人群中,随着年龄的增长,HBsAg 的流行率呈上升趋势,这归因于抗-HBs 随时间推移而逐渐减弱。然而,对密切相关的横断面调查进行综合分析表明,特定年龄组 HBsAg 流行率的增加更可能与生命早期感染的持续存在有关,这可能是由于乙型肝炎疫苗接种在开始引入时的覆盖率不完善。最新研究表明,在 30 年前接种疫苗的大多数人中可以观察到加强针的反应。此外,在成功接种疫苗的个体中,确认的突破性乙型肝炎病毒感染并伴有严重后果的情况极为罕见。迄今为止,尚无令人信服的证据支持在青春期进行加强接种。乙型肝炎疫苗接种保护期的不确定性,特别是在初次接种后 30 年以上,值得进行系统设计的研究,对同一队列的参与者进行纵向随访,这与之前报告的横断面研究不同,有望提供更直接的证据,帮助我们确定是否需要复种乙型肝炎疫苗。